In the context of a viral pandemic, utilisation of health care resources may exceed standard capacity. The impact of potential resource limitation on the needs of a stem cell transplant and bone marrow service needs to be carefully considered. Challenges are likely to include reduced availability of highly specialised health care staff due to illness or allocation to other areas, as well as compromised infrastructure and acute care bed capacity.

Representatives of all adult and paediatric allogeneic stem cell transplant centres in Australia and New Zealand have been in regular communication and have reached a consensus regarding several issues relating to the COVID‐19 pandemic. This document will be updated regularly as the situation changes and published at [bmtsanz.org.au](http://bmtsanz.org.au). Here, we report the first edition of this consensus:Centres will identify backup donor options for patients undergoing allogeneic transplant from interstate and overseas unrelated donors, including haploidentical related donors and cord blood donors. Travel restrictions and illness are likely to reduce the unrelated donor pool.Centres will cryopreserve all international and possibly interstate unrelated donor products before starting conditioning. Cryopreservation by the collecting centre will be requested as a preference for international donors.Donors who have developed COVID‐19 will be excluded for at least 3 months. Refer to updated international guidelines for the management of donors with contact or geographical risk of SARS‐CoV‐2 exposure.[1](#imj14867-bib-0001){ref-type="ref"}, [2](#imj14867-bib-0002){ref-type="ref"}, [3](#imj14867-bib-0003){ref-type="ref"}The Australian Bone Marrow Donor Registry (ABMDR) will update donor questionnaires to include questions specific to risk factors for COVID‐19.Donors and recipients should be screened for symptoms of COVID‐19 prior to commencement of donor mobilisation and recipient conditioning. Routine donor screening is recommended if feasible, although the sensitivity of screening in asymptomatic donors, and optimal timing of this testing, remains uncertain.Centres should attempt to triage transplants. Triage will depend on patient, donor and disease factors. This should include consideration of risks of disease progression or relapse and estimated transplant related mortality. It is not possible to develop a strict triage protocol that would take into account all eventualities or how the COVID‐19 pandemic will evolve. Nevertheless, general suggestions for disease‐based triage are as follows: High priority: Adverse outcomes are expected if transplant is delayed for any reason other than patient factors.Allogeneic transplantationAcute leukaemia with considerations for the disease risk index (DRI) and Haematopoietic Cell Transplant Comorbidity Index (HCTCI)High‐risk myelodysplastic syndrome not responding to bridging therapyAplastic anaemiaSevere combined immune deficiency in childrenAutologous transplantationRelapsed/refractory aggressive lymphoma or Hodgkin lymphomaCentral nervous system (CNS) lymphoma in first remission based on individual patient considerationsMultiple myeloma failing induction therapyIntermediate priority: Patients can be delayed with bridging therapies used where possible to stabilise disease while awaiting transplant.Allogeneic transplantationStable myelodysplastic syndromeStable myelofibrosisAutologous transplantationMultiple myeloma with consideration of collection of autologous cells based on local resourcesRelapsed indolent lymphomaMantle cell lymphoma (MCL) in first remissionHigh‐grade lymphoma in first remissionLow priority: Patients can be delayed with low risk of adverse outcomeAllogeneic transplantationChronic myeloid leukemia (CML) in chronic phaseLow grade lymphoproliferative disorders including Chronic lymphocytic leukemia (CLL) and indolent lymphomaSickle cell diseaseImmunodeficiencyAutologous transplantationAutoimmune diseases (multiple sclerosis, myasthenia gravis, systemic sclerosis)AmyloidosisClinical trials: unless the clinical trial provides standard of care transplantation that patients would otherwise receive.
